Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of stereotactic radiotherapy combined with anlotinib for malignant spinal tumors
ChiCTR1800017928Phase 2Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in spinal neoplasm, sponsored by Peking University Third Hospital. Primary endpoint: local control. Started Aug 2018; status: recruiting.
02
Drugs
anlotinib
03
Conditions
spinal neoplasm
Beyond the preview
Go deeper on ChiCTR1800017928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017928.